Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes

Nicolas Musi, Michael F. Hirshman, Jonas Nygren, Monika Svanfeldt, Peter Bavenholm, Olav Rooyackers, Gaochao Zhou, Joanne M. Williamson, Olle Ljunqvist, Suad Efendic, David E. Moller, Anders Thorell, Laurie J. Goodyear

Research output: Contribution to journalArticle

547 Citations (Scopus)

Abstract

Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK α2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK α2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK α2.

Original languageEnglish (US)
Pages (from-to)2074-2081
Number of pages8
JournalDiabetes
Volume51
Issue number7
StatePublished - 2002
Externally publishedYes

Fingerprint

AMP-Activated Protein Kinases
Metformin
Type 2 Diabetes Mellitus
Skeletal Muscle
Glucose
Liver
Acetyl-CoA Carboxylase
Muscles
Gluconeogenesis
Phosphocreatine
Glycogen
Hypoglycemic Agents
Blood Glucose
Hepatocytes
Adenosine Triphosphate
Phosphorylation
Enzymes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., ... Goodyear, L. J. (2002). Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 51(7), 2074-2081.

Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes. / Musi, Nicolas; Hirshman, Michael F.; Nygren, Jonas; Svanfeldt, Monika; Bavenholm, Peter; Rooyackers, Olav; Zhou, Gaochao; Williamson, Joanne M.; Ljunqvist, Olle; Efendic, Suad; Moller, David E.; Thorell, Anders; Goodyear, Laurie J.

In: Diabetes, Vol. 51, No. 7, 2002, p. 2074-2081.

Research output: Contribution to journalArticle

Musi, N, Hirshman, MF, Nygren, J, Svanfeldt, M, Bavenholm, P, Rooyackers, O, Zhou, G, Williamson, JM, Ljunqvist, O, Efendic, S, Moller, DE, Thorell, A & Goodyear, LJ 2002, 'Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes', Diabetes, vol. 51, no. 7, pp. 2074-2081.
Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O et al. Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51(7):2074-2081.
Musi, Nicolas ; Hirshman, Michael F. ; Nygren, Jonas ; Svanfeldt, Monika ; Bavenholm, Peter ; Rooyackers, Olav ; Zhou, Gaochao ; Williamson, Joanne M. ; Ljunqvist, Olle ; Efendic, Suad ; Moller, David E. ; Thorell, Anders ; Goodyear, Laurie J. / Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes. In: Diabetes. 2002 ; Vol. 51, No. 7. pp. 2074-2081.
@article{3bd4289fd5e34335baafe204b164358e,
title = "Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes",
abstract = "Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK α2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK α2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK α2.",
author = "Nicolas Musi and Hirshman, {Michael F.} and Jonas Nygren and Monika Svanfeldt and Peter Bavenholm and Olav Rooyackers and Gaochao Zhou and Williamson, {Joanne M.} and Olle Ljunqvist and Suad Efendic and Moller, {David E.} and Anders Thorell and Goodyear, {Laurie J.}",
year = "2002",
language = "English (US)",
volume = "51",
pages = "2074--2081",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes

AU - Musi, Nicolas

AU - Hirshman, Michael F.

AU - Nygren, Jonas

AU - Svanfeldt, Monika

AU - Bavenholm, Peter

AU - Rooyackers, Olav

AU - Zhou, Gaochao

AU - Williamson, Joanne M.

AU - Ljunqvist, Olle

AU - Efendic, Suad

AU - Moller, David E.

AU - Thorell, Anders

AU - Goodyear, Laurie J.

PY - 2002

Y1 - 2002

N2 - Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK α2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK α2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK α2.

AB - Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK α2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK α2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK α2.

UR - http://www.scopus.com/inward/record.url?scp=0036299982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036299982&partnerID=8YFLogxK

M3 - Article

C2 - 12086935

AN - SCOPUS:0036299982

VL - 51

SP - 2074

EP - 2081

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -